He said that a previous scan showed that the four spots where cancer was identified were responding to the treatment.
Advertisement
Dr. Tolcher says the world is on the verge of a “golden age” of drug development, where decades of research is about to pay off in treatments and cures which will change the face of medicine.
“In general, people who’ve had a good response to these drugs continue the treatments”, Johnson said, adding that clinical trials on the drugs didn’t give a defined number of treatments.
“Our mission is to accelerate the development of new therapies by taking the unique skills and unequaled expertise that has been cultivated at START and expanding it to other strategic locations around the world”, he said.
He had said in August that he was suffering from a deadly melanoma of skin, which was first discovered in his liver and taken out, but spread to his brain. He said that he will continue to receive regular three-week immunotherapy treatments of pembrolizumab.
“The reason is because the immune system has to focus on something that’s different in the melanoma from the normal cells”, said Ribas, who is not familiar with Carter’s case. Scientists have been seriously exploring using the immune system to battle cancerous cells for decades as an alternative to chemotherapy, radiation therapy, and surgery.
“Keytruda blocks the cancer from telling the immune system to go away, by binding those receptors and preventing the cancer from flipping that off-switch”, he said.
According to experts, the way in which the melanoma treatment process has evolved and advanced over recent years has brought about an entirely new era in both treatment methodology and the realistic prospect of outstanding recoveries.
“In the president’s situation, the doctors were able to find tumors at a very small size”, about 2 millimeters, he said. At that point, his melanoma had spread to his brain and liver.
So what exactly does it mean to be “cancer-free”? “We have been praying for him and are now eager to celebrate with him”.
Advertisement
During his treatment, Carter volunteered on a building project with Habitat for Humanity and was also involved with work at The Carter Center, the human rights organization that he founded after leaving the White House. He then received four rounds of treatment with Keytruda (pembrolizumab), Merck’s anti-PD1 immunotherapy.
